ALK, a global specialty pharmaceutical company, has had its 2030 CO2 reduction targets approved by the Science Based Targets initiative (SBTi), aligning with the goals of the Paris Agreement. The company aims to reduce scope 1 and 2 greenhouse gas emissions by 42% and ensure 80% of scope 3 emissions come from suppliers with science-based targets. ALK's CO2 reduction action plan includes increasing renewable energy, electrifying production equipment and the company fleet, minimizing refrigerant chemical leaks, adopting general energy efficiency measures, and acquiring renewable energy certificates. The company focuses on improving the lives of people with allergies and mitigating climate change.

ALK's CO2 Reduction Targets Approved

Ask a question

Article Frequency

Coverage